LRMR Company Profile and Key Details

LRMR has shown weak momentum, losing -1.54% over the past week and -23.81% over the past quarter, though year-to-date performance is down -16.01%. Short-term trend indicators are mixed aligned (SMA20 57.18%, SMA50 55.73%, SMA200 56.96%). The stock’s 14-day RSI is 72.34 (overbought), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.02% below its high and over 242.86% above its low. Average 10-day trading volume of 1.76 million shares is below the 3-month average of 4.54 million, indicating normal recent market interest.

Larimar Therapeutics, Inc. has 85.59 million shares outstanding. The public float is 43.14 million shares, elevated short interest at 11.18% of float. This equals 6.37 million shares. The short ratio is 6.11 days. Institutional investors hold 84.67% of the float. Insiders own 1.07%. Flynn James E holds 6.21 million shares, Hamilton Thomas Edward has 664.80 thousand shares and BEN-MAIMON CAROLE has 266.83 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Larimar Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.12. This means the shares are trading above this model’s fair value.

Larimar Therapeutics, Inc. generated EPS of -$1.93 over the past year. Five-year average earnings growth is 50.78%. Wall Street analysts project EPS growth of -0.62% annually over the next five years. The latest quarter delivered EPS of -$0.73. The next quarter is forecast at -$0.49. Next year's EPS is expected at -$39.69. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $7.00. The high target offers 526.51% upside. The low target suggests 68.67% downside. The mean target is $16.00. This offers 285.54% upside. Larimar Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 19, 2026, missed forecasts by 65.91%. The prior quarter beat by 56.19%. Over the last six quarters, Apple has recorded several small beats. These include -35.14% in October 30, 2024.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) closed at $4.15 USD, gaining $0.14 (3.49%) from the previous close of $4.01. The stock is currently mid-range between its 52-week high and low $1.73 and $6.42. With a market capitalization of about $355.15 million, Larimar Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.91). Key stats such as the average daily volume over the past year has been around 4.32 million shares, volume is running light vs its 52-week average. Headquartered in Bala Cynwyd, PA, Larimar Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carole S. Ben-Maimon, the company employs approximately 65 people and listed since June 19, 2014. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Larimar Therapeutics, Inc. trades at a P/E ratio of -2.17, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.6 trading at moderately above to book value. The P/FCF stands at -3.18, also below market averages.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) shares are down -16.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Larimar Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.17. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $15.77, suggesting 280.0% upside. Our AI forecast model points to short-term weakness (-10.6% over two weeks), a medium-term rise (149.88% over three months), and a longer-term gain (265.54% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Larimar Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.6%, with price expected at $3.71 by May 20, 2026, within a range of $3.50 to $3.91 3-Month Outlook: Projected rise of 149.88%, reaching $10.37 by August 04, 2026, with a range of $10.17 to $10.57. 1-Year Outlook: Projected gain of 265.54%, with price at $15.17 by May 06, 2027, within a range of $8.15 to $21.95.